HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


German Women's Supplements Specialist InnoNature Secures Private-Equity Backing

Executive Summary

Germany's Innonature - which develops and markets supplements, superfoods and cosmetics for women - has been snapped up by Northern European private-equity firm Verdane.

You may also be interested in...

Amazon-Exclusive And Hybrid Selling Strategies Deliver Success For German Wellness Brands

Amazon is becoming an increasingly important retail channel for the German wellness market. An analysis of best-selling categories, Omega 3, vitamin B and probiotic supplements, by Sempora Consulting suggests a mixture of exclusive and hybrid selling strategies can deliver results.

OTC Oral Contraceptive In US Would Bring Market Uncertainties Along With Public Health Benefits

Perrigo is the top potential marketer of the first OTC oral contraceptive in the US by acquiring HRA Pharma, which is preparing a switch NDA and earlier in 2021 gained UK regulatory approval for pharmacy sales of a progestin-only contraceptive, desogestrel.

HRA Pharma And Maxwellia To Launch The UK’s First OTC Daily Contraceptives

The UK's MHRA has approved the Rx-to-OTC switch of two identical progestogen-only contraceptive pills from HRA Pharma and Maxwellia. Hana and Lovima (both 75mcg desogestrel) will be launched at the end of the month. 

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts